Seeking Alpha

Endocyte (ECYT +6.1%) ramps higher after Baird upgrades the stock to Outperform with a $13 price...

Endocyte (ECYT +6.1%) ramps higher after Baird upgrades the stock to Outperform with a $13 price target and says the company's chemo drug Vintafolide should be a "catalyst" going forward. 
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs